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Sunitinib depletes myeloid-derived suppressor
cells and synergizes with a cancer vaccine to
enhance antigen-specific immune responses and
tumor eradication
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Abbreviations: ARG1, arginase-1; CTL, cytotoxic T lymphocyte; DC, dendritic cell; HPV, human papilloma virus; Flt3, Fms-like
tyrosine kinase 3; iNOS, nitric oxide synthase; MDSC, myeloid-derived suppressor cell, mRCC, metastatic renal cell carcinoma;
PBMC, peripheral blood mononuclear cell; rSFV, recombinant Semliki forest virus; Treg, regulatory T cell; TGFb, transforming
growth factor b; VEGF, vascular endothelial growth factor receptor.
The high efficacy of therapeutic cancer vaccines in preclinical studies has yet to be fully achieved in clinical trials.
Tumor immune suppression is a critical factor that hampers the desired antitumor effect. Here, we analyzed the
combined effect of a cancer vaccine and the receptor tyrosine kinase inhibitor sunitinib. Sunitinib was administered
intraperitoneally, alone or in combination with intramuscular immunization using a viral vector based cancer vaccine
composed of Semliki Forest virus replicon particles and encoding the oncoproteins E6 and E7 (SFVeE6,7) of human
papilloma virus (HPV). We first demonstrated that treatment of tumor-bearing mice with sunitinib alone dose-
dependently depleted myeloid-derived suppressor cells (MDSCs) in the tumor, spleen and in circulation. Concomitantly,
the number of CD8C T cells increased 2–fold and, on the basis of CD69 expression, their activation status was greatly
enhanced. The intrinsic immunosuppressive activity of residual MDSCs after sunitinib treatment was not changed in a
dose-dependent fashion. We next combined sunitinib treatment with SFVeE6,7 immunization. This combined
treatment resulted in a 1.5- and 3-fold increase of E7-specific cytotoxic T lymphocytes (CTLs) present within the
circulation and tumor, respectively, as compared to immunization only. The ratio of E7-specific CTLs to MDSCs in blood
thereby increased 10- to 20-fold and in tumors up to 12.5-fold. As a result, the combined treatment strongly enhanced
the antitumor effect of the cancer vaccine. This study demonstrates that sunitinib creates a favorable
microenvironment depleted of MDSCs and acts synergistically with a cancer vaccine resulting in enhanced levels of
active tumor-antigen specific CTLs, thus changing the balance in favor of antitumor immunity.
Introduction
Immunotherapy against cancer aims at the induction and sub-
sequent migration of tumor-antigen specific T cells into the
tumor. This can be achieved by therapeutic immunizations gen-
erating tumor antigen-specific T cells in combination with treat-
ments that enhance intratumoral infiltration of T cells.1,2
However, intratumoral immunosuppressive cells may hamper
immune-based tumor eradication, despite the presence of tumor
antigen-specific T cells.3
Myeloid-derived suppressor cells (MDSCs) are immunosup-
pressive cells of myeloid origin composed of immature
macrophages, granulocytes and dendritic cells. Increased levels of
MDSCs have been reported in spleen, bone marrow and circula-
tion in tumor-bearing animals and cancer patients.4 Intratumoral
MDSC levels correlate with tumor progression, metastasis and
resistance to cancer therapies.5,6 In mice, MDSCs are identified
by the simultaneous expression of the myeloid antigens CD11b
and Gr-1 on their cell membrane. MDSCs can suppress T-cell
functions via inducible nitric oxide synthase (iNOS) and argi-
nase-1 (ARG1).7,8 To overcome the immunosuppressive effects
of MDSCs and potentiate antitumoral immune responses, deple-
tion or functional inhibition of MDSCs in combination with
immunization regimens could be an option. 9,10
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ORIGINAL RESEARCH
Sunitinib malate is an oral, broad spectrum, receptor tyrosine
kinase inhibitor currently used as a first-line therapy of metastatic
renal cell carcinoma and for treatment of gastrointestinal stromal
tumors resistant to conventional therapy.11-13 The mechanism of
action of sunitinib consists of blockade of several receptor tyro-
sine kinases localized on both tumor cells and MDSCs, such as
vascular endothelial growth factor receptor (VEGFR), Flt3 Fms-
like tyrosine kinase 3 (Flt3) and c-kit (CD117).14 Previous stud-
ies have shown that blockade of these receptors skew MDSCs
towards an immunosuppressive phenotype15 and reverse immune
tolerance in a variety of murine tumor models.16-18
We developed a cancer vaccine against human papillomavirus
(HPV) induced cancer, based on a recombinant alphavirus,
namely Semliki Forest virus (rSFV). The rSFV replicon particles
encode a fusion protein of HPV type 16 E6 and E7 derived from
HPV type 16 (termed SFVeE6,7). Immunization with SFVeE6,7
particles generates high levels of HPV-specific T cells and eradi-
cates established HPV-transformed tumors. Using an HPV
tumor model in mice, we studied the effect of sunitinib on intra-
tumoral MDSC accumulation and activity of intratumoral anti-
gen-specific T cells. This study aimed to determine if the efficacy
of a cancer vaccine could be enhanced by depletion or functional
inactivation of the immunosuppressive MDSC population.
Results
Effect of sunitinib on intratumoral and intrasplenic levels of
MDSCs and Tregs
We first determined the effect of sunitinib on MDSC accu-
mulation in tumors and spleens of TC-1 tumor-bearing mice.
Starting day 15 after tumor inoculation, mice received sunitinib
daily for a period of 9 days. Subsequently, the levels of MDSCs
in tumors and spleens were assessed by immunostaining and fluo-
rescence cytometry (Fig. S1). The absolute numbers of both
intratumoral and intrasplenic MDSCs decreased dose-depen-
dently (Fig. 1A, Fig. S2B). As MDSCs have been shown to
induce expansion of regulatory T cells (Tregs,19 we also deter-
mined the effect of sunitinib on Treg levels. Sunitinib slightly,
but not significantly, decreased numbers of intratumoral and
intrasplenic Tregs. Only the highest dose of sunitinib resulted in
a significant decrease of Tregs (Fig. 1B). However, as this highest
dose of sunitinib resulted in weight loss of the mice, this dosage
was not used in further experiments.
Effect of sunitinib on intratumoral and intrasplenic levels of
CD8C T cells
We next, set out to determine the effect of sunitinib on the
intratumoral and intrasplenic levels of CD8C T cells, as well as
the fraction of CD8C T cells positive for CD69, the earliest
inducible cell surface glycoprotein acquired during lymphocyte
activation (Fig. S3).20 The absolute numbers of both intratu-
moral and intrasplenic CD8C T cells increased dose-dependently
(Fig. 1C, black bars, and Fig. S2C). More than 95% of CD8C T
cells isolated from the primary tumors and spleens of the
untreated group were negative for the activation marker CD69.
Notably, more than 50% of CD8C T cells were positive for
CD69 after sunitinib treatment, irrespective of the dosage
employed (Fig. 1C, white bars). These results indicate that suni-
tinib treatment not only increases the numbers but also the
expression of the activation marker CD69 on the surface of intra-
tumoral and intrasplenic CD8C T cells (Fig. S3).
Combined effect of immunization and sunitinib on
intratumoral and intrasplenic levels of total and E7-specific
CD8C T cells, MDSCs and Tregs
We next investigated the combined effect of sunitinib and
viral vector immunization on intratumoral and intrasplenic levels
of different immune cell populations. Mice were i.m. injected
once on day 14 after tumor inoculation with 5£106 SFVeE6,7
particles. Sunitinib treatment was started the following day, with
20 or 40 mg/kg body weight i.p., and continued for a period of
9 consecutive days. On day 24 tumors and spleens were harvested
and analyzed. The priming SFVeE6,7 immunization did not
influence the depletion of intratumoral and intrasplenic MDSCs
induced by sunitinib (Fig. 2A versus Fig. 1A). Also the number
of Tregs was not altered by SFVeE6,7 priming (Fig. 2B versus
Fig. 1B).
Notably, the combination of immunization and sunitinib led
to an increase in intratumoral and intrasplenic CD8C T cells, as
compared to SFVeE6,7 immunization or sunitinib treatment
alone (Fig. 2C versus Fig. 1C), coincident with an increase
in the number of antigen-specific CD8C T cells (Fig. 2D and
Fig. S4).
Remarkably, with a sunitinib dose of 40 mg/kg body weight,
the ratio of E7-specific CD8C T cells to MDSCs increased 12.5-
fold, from 0.1:1 upon immunization only, to 1.25:1 after com-
bined sunitinib and immunization treatment.
Intrinsic immunosuppressive activity of MDSCs after
sunitinib treatment
Next, MDSCs were isolated and their intrinsic suppressive
activity was determined ex-vivo. MDSCs isolated from TC-1
tumors of PBS- or sunitinib-treated mice were co-cultured with
splenocytes isolated from SFVeE6,7 immunized mice. Cytolytic
activity and proliferation of CD8C T cells were measured after
7 days of co-culture.
Cytolytic activity of CD8C T cells, in the absence or presence
of MDSCs, was measured in a chromium51 release assay, in
which C3 tumor cells were used as target cells and the effector to
target cell ratio was 100:1. The percentage of cytotoxicity
decreased from »70-75% in the asbsence of exogenous MDSCs
to »55% and »25-30% at MDSC to splenocyte ratios of 3:100,
and 6:100, respectively. The addition of 25 MDSCs per 100
splenocytes completely blocked cytolysis (Fig. 3A). The inhibi-
tory effects between MDSCs isolated from tumors of the PBS or
sunitinib treated groups did not differ.
Proliferation of E7-antigen specific T cells in the absence or
presence of MDSCs at the above-mentioned ratios were mea-
sured by carboxyfluorescein succinimidyl ester (CFSE)-labeling
of cells on day 4 and flow cytometric analysis on day 7 of co-cul-
ture. In the absence of additional MDSCs, the percentage of
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proliferation was »80%, similar to that
when MDSCs were added at an MDSC
to splenocyte ratio of 3:100 and 6:100,
respectively. However, at an MDSC to
splenocyte ratio of 25:100 the percentage
of proliferation decreased to 1–5%
(Fig. 3B and Fig. S5). This inhibitory
effect on proliferation was also not influ-
enced by sunitinib treatment.
We next analyzed changes in mRNA
levels of different enzymes and factors
that have been previously implicated as
being responsible for MDSC-mediated
immune suppression, such as arginase-1
(ARG1), inducible nitric oxide synthase
(iNOS) and transforming growth factor
b (TGFb).8,21 Thus, we analyzed
changes in mRNA levels of these factors
in MDSCs isolated from tumors of PBS-
or 40 mg/kg body weight sunitinib-
treated mice. The fold expression of these
factors in MDSCs isolated from tumors
of sunitinib-treated mice was similar to
those in MDSCs isolated from tumors of
PBS-treated mice (Table S2).
Taken together, these results suggest
that sunitinib treatment induced a
decrease in circulating as well as intratu-
moral MDSCs, while no change in
intrinsic activity of intratumoral MDSCs
was observed upon sunitinib treatment.
In vivo antitumor response of
combinatorial treatment and effect on
blood immune cells
We have previously shown that opti-
mal immunization with an SFVeE6,7
dosage of 5£106 particles administered i.
m. on days 7, 14, 21 after TC-1 tumor
inoculation leads to complete tumor regression in all mice.22 In
order to evaluate the additive effect of sunitinib we immunized
mice with two different suboptimal immunization schedules and
dosages. For the first suboptimal regime, mice were immunized
with the standard dose of 5 £ 106 SFVeE6,7 particles, adminis-
tered i.m. starting at a late time point after tumor inoculation
and only twice, i.e., on days 14 and 21 after tumor inoculation.
The second suboptimal regimen involved immunization with a
suboptimal dose of vaccine, i.e. 1£106 SFVeE6,7 particles,
administered i.m. also starting at a late time-point, i.e., 14, 21
and 28 after tumor inoculation. These stringent suboptimal
SFVeE6,7 regimens, used in combination with sunitinib, would
allow us to monitor temporal changes in levels of circulating
immune cells as well as tumor growth. Sunitinib treatment
(40 mg/kg body weight, i.p.) was started on day 7 after tumor
inoculation. This created an intratumoral immune environment
deprived of MDSCs and enriched in CD69C E7-specific CD8C
T cells (Fig. S6A and B).
Sunitinib alone neither delayed nor promoted tumor growth
as compared to the untreated group (Fig. 4) and mice had to be
sacrificed at the same time point. This result indicates that,
despite the fact that concentrations of sunitinib higher than
1 mM induce TC-1 cell death in vitro, 40 mg/kg body weight as
employed in vivo does not seem to directly affect tumor growth.
The 2 suboptimal SFVeE6,7 immunization regimens alone still
resulted in a delay in tumor growth as compared to the PBS or
sunitinib treated groups (Fig. 4). In contrast, in the group of
mice receiving sunitinib followed by the first suboptimal immu-
nization regime, (i.e., only receiving 2 immunizations, starting at
a late time point with a standard dose of SFVeE6,7) 66% sur-
vived up to day 62 post inoculation (Figs. 4 and 5A). Notably,
the combination of a low dose immunization with sunitinib
Figure 1. The effect of sunitinib treatment on intratumoral MDSC, Tregs, CD8C T cells and activation
status of the CD8 T cell population. C57Bl6 mice were subcutaneously inoculated with TC-1 tumor
cells (n D 3–6 mice/group). On day 15 after tumor inoculation, sunitinib treatment was started, daily,
i.p., for a period of 9 consecutive days. Three increasing dosages of sunitinib were used: 20, 40 and
60 mg/kg body weight. Mice were sacrificed and tumors and spleens were harvested. The levels of
(A) MDSCs (CD11bCGr1C), (B) Tregs (CD4CFoxP3C), (C) CD8C T cells (CD8C; black bars) and the acti-
vation status of CD8C T cells (CD69C; white bars) were analyzed by immunostaining and multicolor
fluorescence cytometry. Experiments were repeated twice. Shown here are averages and SD for
each experimental group (*p < 0.05; **p < 0.01; ***p< 0.001).
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increased survival up to 75% (Figs. 4 and 5A). It should be noted
that, for ethical reasons, mice had to be sacrificed when tumors
protruded through the skin, irrespective of tumor size. This
explains why, despite the fact that most of the tumors regress in
the combined treatment groups, not all the mice survived up to
day 60.
Upon in vitro incubation of TC1 cells with increasing
concentrations of sunitinib a >20% decrease in viability was
observed at concentrations higher than 2.5 mM of sunitinib
(Fig. S7). Similar effects have been previously observed by
others.23-25 Although a direct comparison with the in vivo
treatment is difficult, this concentration is apparently not
achieved in vivo, as the in vivo treat-
ment with sunitinib at a dose of
40 mg/kg did not arrest tumor growth
or delay tumor development.
Within these groups of mice we also
analyzed the changes in immune cells in
the blood during the treatment period.
Seven days after tumor inoculation, circu-
lating MDSC levels were maximally 1%
of the total peripheral blood mononuclear
cell (PBMC) population. However, at
days 14, 21 or 28 after tumor inoculation,
circulating MDSC levels increased to
almost 20% of the total PBMCs in the
groups that did not receive sunitinib. In
the sunitinib treated groups MDSCs
increased from 1% to maximally 5% of
the total PBMCs (Fig. 5B).
Levels of E7-specific CD8C T cells
were lower than 0.1% of the total PBMCs
in all groups on days 7 and 14 after tumor
inoculation. Notably, on day 21 post
inoculation levels of E7-specific CD8C T
cells increased to »10-15% in all groups
receiving SFVeE6,7. These levels were
maintained constant up to day 28
(Fig. 5C). Remarkably, the combination
of immunization and sunitinib enhanced
E7-specific CD8C T cells:MDSC ratio
11-fold, specifically from 0.5:1 for the
group receiving 2 dosages of 5 £ 106
SFVeE6,7 to 5.55:1 for the group receiv-
ing both immunization and sunitinib.
Similarly, a 21-fold increase in the E7-
specific CD8C T cells:MDSC ratio was
observed between the group receiving 3
dosages of 1£106 SFVeE6,7 and the
group receiving double treatment
(Table 1). The proportion of total CD8C
T cells increased from 10% on days 7 and
14 post tumor inoculation to 17% of the
total PBMCs in all groups receiving PBS
or single treatment. In contrast, in mice
that received SFVeE6,7 immunization
combined with sunitinib, the levels of CD8C T cells increased
dramatically to 40% of total PBMCs (Fig. S8A).
Circulating levels of neutrophils (CD11bC) and dendritic cells
(CD11cC) were enhanced in all groups from »1% on day 7 post
inoculation up to »10% and 10–20%, respectively, of total
PBMCs on days 14, 21, 28 post inoculation (Fig. S8B and C).
Discussion
Tumor growth is often associated with the development and
maintenance of an immunosuppressive tumor microenvironment.
Figure 2. Therapeutic immunization and sunitinib enhance intratumoral and intrasplenic levels of
total CD8C T cells, but not MDSC and Tregs. Mice were s.c. inoculated with TC-1 tumor cells (n D 3
mice/group). On day 14 after tumor inoculation mice were vaccinated once, i.m., with 5 £ 106
SFVeE6,7 particles. One day later, sunitinib treatment of 20 and 40 mg/kg body weight was started,
i.p., for a period of 9 consecutive days. The levels of (A) MDSCs (Gr1CCD11bC), (B) Tregs
(CD4CFoxP3C), (C) activated total CD8C T cells (CD8CCD69C), and (D) activated E7-antigen specific
CD8C T cells (CD8CE7CCD69C) in tumors and spleens were analyzed by immunostaining and fluo-
rescence cytometry on day 24. Experiments were repeated twice. Shown here are averages and SD
for each experimental group (*p < 0.05).
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Accumulation of intratumoral MDSCs
is one of the factors contributing to the
phenomenon of tumor immune
escape.26,27 Recently, studies have
reported that some chemotherapeutic
drugs do not solely target tumor cells
but also enhance antitumor immunity.28
Additionally, these drugs can negatively
regulate immunosuppressive MDSCs
and Treg populations.29,30 One such
drug, used in the clinical setting for
treatment of metastatic renal cell carci-
noma,31 is the receptor tyrosine kinase
inhibitor sunitinib.
In this study, we demonstrate that
immunization with a cancer vaccine
combined with clinically relevant doses
of sunitinib32,33 strongly augments the
levels of total and antigen-specific T
cells in the circulation, tumor and
spleen of tumor-bearing mice. Simulta-
neously, intratumoral, intrasplenic and
circulating levels of MDSCs are strongly
diminished. Overall, this combination
therapy leads to a strong increase in the
ratio of antitumor immune effector cells
to immunosuppressive cells within the
tumor. Moreover, combined sunitinib
and sub-optimal vaccination strategies
induce abrogation of tumor growth. This study shows that suniti-
nib can further enhance cancer vaccine-induced immune
responses and antitumor effects.
A feature that makes sunitinib an attractive drug for cancer
treatment is its reported lower toxicity as compared to similar
tyrosine kinase inhibitors, such as the monoclonal humanized
anti-VEGF antibody bevacizumab or the mTOR kinase inhibitor
temsirolimus.34 The most common grade 3/4 treatment related
adverse events when using sunitinib in the pivotal Phase I clinical
trial for the treatment of patients with metastatic renal cell carci-
noma were fatigue and thrombocytopenia.12 Sorafenib and pazo-
panib, 2 other novel tyrosine kinase inhibitors reported to reduce
MDSC levels in murine models of colon and Lewis lung carci-
noma,35 may have reduced side-effects as compared to suniti-
nib.34 Nevertheless, in addition to the direct tumor targeting and
MDSC depleting effects in patients with renal cell carcinoma
(RCC), sunitinib also enhanced restoration of T helper type 1
(Th1) cells and induced a stable decrease in Tregs.36-38 Various
studies have demonstrated the well-known antiangiogenic and
direct tumoricidal activity of sunitinib,39,40 developed through
pleiotropic effects exerted on the receptors of vascular endothelial
and platelet-derived growth factors, as well as Flt-3 and the c-kit
oncogene.33,41 However, the effect of sunitinib on activation sta-
tus and levels of immune cells has not yet been fully elucidated.
Several groups have previously reported the effect of sunitinib
on MDSCs. In an MCA26 mouse colon carcinoma model, treat-
ment with sunitinib decreased the numbers and functionality of
MDSCs and Tregs, while concurrently enhancing both intra-
tumoral and intrasplenic CD8C T cell levels and responses
among tumor-infiltrating lymphocytes (TILs).29 Similar results
were observed in the murine Renca tumor model where the anti-
angiogenic and depleting effects of sunitinib were mediated
through inhibition of signal transducer and activator of transcrip-
tion 3 (Stat3).23 The selective effect of sunitinib in enhancing lev-
els and activity of CD8C TILs might be due to diminished
expression of the negative co-stimulatory molecules programmed
cell death 1 (PDCD1), programmed cell death ligand 1 (PDL1)
and cytotoxic T lymphocyte-associated protein 4 (CTLA4).29
Consistent with previous reports,42,43 in our study sunitinib
enhanced the intratumoral, intrasplenic and circulating numbers
and activation status of CD8C T lymphocytes. In 2 other murine
tumor models (C26 colon and 4T1 mammary carcinomas), suni-
tinib only seems to deplete splenic, but not intratumoral
MDSCs.37,44
We expect that the molecular mechanisms of MDSC deple-
tion by sunitinib involves Stat3 blockade as well as decreasing
expression of vascular endothelial derived growth factor receptor
(VEGFR) by MDSCs.23,37,45 Stat3 activation has been shown to
stimulate expression of proliferative genes in immature myeloid
cells, thus leading to their subsequent development into MDSCs.
VEGFR interacts with its corresponding VEGF ligand expressed
on tumor cells. Blockade of these 2 factors would thus result in a
diminished number of circulating MDSCs, with a lower capacity
to migrate to the tumor site. The effect of sunitinib observed in
Figure 3. MDSCs isolated from tumors of TC-1 tumor-bearing mice suppress the anti-tumoral activity
of CD8C T cells. TC1 tumor-bearing mice (n D 5–7 mice/group) were divided in two subgroups, the
first subgroup receiving PBS and the second receiving 40 mg/kg body weight sunitinib, i.p., for a
period of nine consecutive days. At the end of the experiment, intratumoral MDSCs were isolated and
positively sorted (CD11bCGr1C). A separate group of mice received 2 SFVeE6,7 immunizations, in a
dosage of 5 £ 106 particles, on days 0 and 14. This group of mice was then sacrificed 10 days later
and splenocytes were isolated and co-cultured with different ratios of MDSCs (isolated from the first
two subgroups and positively sorted) for a period of 7 days. (A) A 51Chromium release assay was per-
formed to determine the suppressive effect of MDSCs. The target cells used in this assay were C3
tumor cells expressing the full HPV16 genome. (B) On day 4 of co-culture, a portion of the cells were
labeled with carboxyfluorescein succinimidyl ester (CFSE). On day 7 of co-culture, the E7-antigen spe-
cific CD8C T-cell proliferation was determined by multicolor fluorescence cytometry. Experiments
were repeated twice. Shown here are averages and SD for each experimental group (*p < 0.05;
***p < 0.001).
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this study cannot be ascribed to an inhibition of Tregs as only a
dosage of 60 mg/kg of sunitinib significantly suppressed the
number of Tregs. In the combination studies of SFVeE6,7 and
sunitinib this high dosage was not used. Furthermore, we have
shown before that in this
tumor model Tregs do not
play a major role in intratu-
moral immune suppres-
sion.46 Previously, it was
reported that sunitinib has
no effect on human den-
dritic cells (DCs), as incu-
bation of sunitinib with
DCs did not reduce their
cytokine secretion or




our study, sunitinib treat-
ment, alone or in combina-
tion with immunization,
did not affect circulating
levels of DCs.
A recent study by Aliza-
deh et al. showed that
doxorubicin, in addition to
diminishing levels of
MDSCs, also blocks the
immunosuppressive func-
tions of the residual,
non-depleted MDSCs.42
Because of this, we investi-
gated the potential effects
of sunitinib on the func-





sible for the suppressive




growth factor b (TGFb).
Various studies have shown
that ARG1 and iNOS
deplete the nonessential
amino acid L-arginine, a




TGFb has been reported to
negatively affect functions
of cytotoxic T cells.47 In our study, no significant changes were
observed in the mRNA levels of these and other enzymes and fac-
tors between MDSCs isolated from tumors of sunitinib- or PBS-
treated mice. In contrast to doxorubicin treatment, sunitinib did
Figure 4. Combination of sunitinib and therapeutic vaccination abrogates tumor growth. Mice (nD 4–6/group) were
s.c. inoculated with TC-1 tumor cells. On day 7 after tumor inoculation, sunitinib treatment was started, daily, i.p., for
a period of 9 consecutive days. Mice where then immunized with SFVeE6,7 i.m., either on days 14 and 21 after tumor
inoculation with a dosage of 5 £ 106 particles, or on days 14, 21, and 28 with a dosage of 1 £ 106 particles, respec-
tively. Tumor measurements were performed periodically; when tumor size exceeded 1000 mm3 or when tumors
protruded through the skin (#) mice were sacrificed due to ethical reasons. Experiments were repeated at least twice.
Shown here are the tumor growth curves for each experimental group, per mouse.
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not change the intrinsic functional activity of residual MDSCs.
Furthermore, sunitinib treatment did not change the levels of
MDSC-induced immunosuppressive enzymes and factors.8
There are only very few studies to date that combined suniti-
nib and vaccination therapy. Our study is most consistent with a
study performed in a murine model of MC38 colon carcinoma
showing that sequential administration of sunitinib and a poxvi-
rus-based vaccine enhanced antitumor activity as compared to
either treatment alone.48 In their study sunitinib was given orally
and preceded and overlapped with the priming and booster
immunizations. We additionally demonstrate that sunitinib
treatment starting one day after vaccine administration increased
the numbers of intratumoral E7-specific CTLs and decreased
MDSCs. In a previous study, we determined the effector cell
types responsible for the antitumor effect generated by SFVeE6,7
immunization. The CD8C, CD4C or both T cells subsets were
depleted in vivo with monoclonal antibodies. In the group of
mice immunized with SFVeE6,7 with or without CD4C T-cell
depletion, all mice were protected from tumor outgrowth. In
contrast, in the group of immunized mice depleted of CD8C T
cells all mice developed tumors within two weeks.49 Thus, the
immunomodulatory effects of the combined sunitinib and
immunization treatment seem to change the intratumoral
immune balance towards antitumor immunity.
Figure 5. Combination of therapeutic immunization and sunitinib stably decreases circulating MDSC levels, enhances levels of E7-specific CD8C T cells
and abrogates tumor growth. Mice (n D 4–6/group) were s.c. inoculated with TC-1 tumor cells. On day 7 after tumor inoculation, sunitinib treatment was
started, daily, i.p., for a period of 9 consecutive days. Mice where then immunized with SFVeE6,7 i.m., either on days 14 and 21 after tumor inoculation
with a dosage of 5 £ 106 particles, or in days 14, 21 and 28 with a dosage of 1 £ 106 particles, respectively. (A) The percentage of tumor-free survival
was determined at the end of experiments. At specific time intervals, blood was drawn and used to identify the levels of (B) MDSCs (CD11bCGr1C) and
(C) E7-specific CD8C T cells (E7CCD8C) by immnostaining and fluorescence cytometry. Statistical differences between groups that received sunitinib
treatment, alone or in combination with immunization, and groups that received only SFVeE6,7 immunization or PBS are shown. Depicted here are aver-
ages and SD for each experimental group (*p < 0.05).
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We further show that immunization following a 9-day suniti-
nib treatment strongly enhances the antitumor responses. This
latter observation contrasts with findings of a recent study of Jaini
R et al. using a 4T1 mammary tumor model in which they found
sunitinib treatment inhibited immune priming due to a decrease
in antigen-presenting cells and only immunization prior to suni-
tinib resulted in antitumor immune responses.50 This difference
is remarkable but might be due to the vaccine employed (alpha-
lactalbumin) or the tumor model involved. Considering that
sunitinib has such a marked effect on the immunization efficacy
of our SFVeE6,7 vaccine, further studies seem warranted to
unravel this difference in response. In our study, the intratumoral
depletion of MDSCs and the concomitant increase in E7-specific
T cells translated into a substantial increase in the ratio of effector
antigen-specific CD8C T cells to MDSCs. In addition, we show
that these effector antigen-specific CD8C T cells upregulate
CD69, indicating activation of these cells. These findings may, at
least partially, explain the in vivo antitumor results showing that
combination of sunitinib with sub-optimal immunization abro-
gates tumor growth.
Taken together, our results report a synergistic effect of com-
bined sunitinib treatment with cancer vaccine therapy in generat-
ing an immunological environment depleted of MDSCs and
enriched in activated antitumoral E7-antigen specific cytotoxic T
lymphocytes, favorable to tumor regression. Thus, this bimodal
therapy changed the immunological balance in favor of antitu-
mor immunity by simultaneously enhancing the tumor antigen-
specific fraction as well as depleting protumoral immune cells, an
immunological response beneficial to treatment outcome. These
results provide compelling rationale for the clinical implementa-
tion of sunitinib and therapeutic antitumoral immunizations, to
enhance the effectiveness of immunotherapy.
Materials and Methods
Cell lines
Baby hamster kidney cells (BHK-21) were obtained in 1996
from the American Type Culture Collection (# CCL-10). The
TC-1 cell line, generated from C57Bl/6 primary lung epithelial
cells with a retroviral vector and expresses human papillomavirus
16 (HPV16) E6E7, was obtained in 1998 from Prof. dr. Cornelis
Melief (Leiden University Medical Center, Leiden, The Nether-
lands). The C3 cell line was obtained in 1998 from Dr. Mariet
Feltkamp and Prof. dr. Jan ter Schegget (Leiden University Med-
ical Center, Leiden, The Netherlands). Cell lines were authenti-
cated by morphology and growth characteristics, tested for
mycoplasma and frozen, and cells were cultured for less than 3
months. The TC1 cell line was also tested for E6, E7 by western
blot and for MHC Class I RAHYNIVTF expression by FACS
analysis prior to freezing. After thawing, cells were cultured as
previously described22 and growth kinetics were recorded and
validated twice weekly.
Cell viability assay
To determine cell viability of TC-1 tumor cells in the absence
or presence of different concentrations of sunitinib, TC-1 tumor
cells were plated into 96-well plates at a density of 104 cells per
well and left to adhere overnight in IMDM medium (Iscove’s
modified Dulbecco’s medium, Gibco, Invitrogen, catalog nr.
31980030) supplemented with 10% fetal calf serum (FCS). Sub-
sequently, cells were incubated with 1.25 mM, 2.5 mM, 5 mM,
10 mM, 20 mM, 30 mM or 40 mM sunitinib solution, for a
period of 24 h. Next, viability was quantified using a standard
MTT assay kit (Sigma Aldrich, catalog nr. TOX1-1KT). The
results were expressed as mean viable cells relatively to viability of
TC-1 alone (considered as 100% viability) § SD. The assay was
performed in replicates of 6 and repeated three times.
Mice
Specified pathogen-free female C57BL/6 mice were used at 8 to
10 weeks of age. The mice were purchased from Harlan CPB and
kept according to institutional guidelines. The local Animal Exper-
imentation Ethical Committee approved all animal experiments.
Production, purification and titer determination of
SFVeE6,7 particles
Production, purification and titer determination of SFVeE6,7
was performed as described previously. 51 In brief, SFVeE6,7 par-
ticles were produced by co-electroporation of BHK-21 cells with
an RNA encoding the SFV replicase and the transgene (the E6E7
fusion protein) and a helper RNA encoding the structural pro-
teins of SFV. Recombinant SFV replicon particles produced by
transfected BHK-21 cells were purified on a discontinuous
sucrose density gradient. rSFV particles were titrated on BHK-21
cells using a polyclonal rabbit anti-replicase (nsP3) antibody [a
gift from Dr. T. Ahola (Biocentre Viikki, Helsinki)].
Tumor inoculation, SFVeE6,7 immunizations, and sunitinib
treatment
Mice were inoculated subcutaneously in the neck with 2£104
TC-1 cells52 suspended in 0.2 mL Hank’s Balanced Salt Solution
(Invitrogen, catalog nr. 14025092). As tumor growth slightly
varies, mice were, at the start of treatments, divided into groups
Table 1. Ratios between total CD8C T cells or HPV E7-specific CTLs and MDSCs in blood following sunitinib treatment alone or in combination with SFVeE6,7
immunizations at day 28 after tumor inoculation.
Ratio PBS S40 5 £106SFVeE6,7 S40C5 £106SFVeE6,7 1 £106SFVeE6,7 S40C1 £106SFVeE6,7
E749-57tetr
CCD8C/ MDSC n.d. n.d. 0.50 5.55 0.49 10.40
Total CD8C/MDSC n.d. n.d. 0.91 10.33 0.88 22.86
CTL, cytotoxic T lymphocyte; MDSC, myeloid-derived suppressor cell; n.d., not determined; PBS, phosphate buffered saline.
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such that each group contained mice with tumors of equal varia-
tions in size. Sunitinib 20, 40 or 60 mg/kg body weight was
administered intraperitoneally for 9 consecutive days, starting
day 7 or 15 after tumor inoculation.37 Some groups received
intramuscular SFVeE6,7 immunizations in a dosage of 106 or
5£106 particles. All SFVeE6,7 immunizations were administered
in the hind legs of the mice in a total volume of 50 mL (25 mL/
hind leg). Tumor dimensions were assessed using calipers, and
the tumor volume was determined using the formula: volume D
[length £ (width)2] £ 0.5. According to the guidelines of the
local ethical committee, mice were sacrificed when losing more
than 15% of weight, when tumors exceeded 1000 mm3, pro-
truded through the skin or at the end of experiments.
Tumor digestion and splenocyte isolation procedures
At the end of experiments tumor-bearing mice were sacrificed
and tumors and spleens were isolated. Tumors were weighed, cut
into small pieces and re-suspended in digestion medium [1 mg/
mL Collagenase A (Roche, catalog nr. 10103578001) in
WiIliam’s E medium (Gibco, Invitrogen, catalog nr. 32551-020)
pre-warmed to 37oC. Tumors were homogenized using the gen-
tleMACSTM Dissociator (MiltenyiBiotec) according to the man-
ufacturer’s instructions and incubated for 30 min at 37oC on a
shaker (120 rpm). Next, tumors were homogenized one more
time and incubated for another 30 min at 37oC on a shaker
(120 rpm). After digestion, cells were filtered through a 70 mm
Falcon cell strainer (BD Biosciences).
Spleens were weighed, cut into small pieces and re-suspended
in IMDM medium with 5% FCS, 100 U/mL penicillin and
100 mg/mL streptomycin. The suspension was filtered through a
70 mm Falcon cell strainer, centrifuged and resuspended by tick-
ing. Erythrocytes were lysed for 5 min at room temperature with
5 mL of sterile erythrocyte lysis buffer (150 mM NH4Cl,
10 mM KHCO3, 0.1 mM Na2-EDTA pH D 7.2–7.4). The
reaction was stopped with 15 mL IMDM medium; after centri-
fugation, the supernatant was discarded, cells were resuspended
in IMDM medium with 5% FCS.
Cell sorting and co-culture
Freshly isolated tumor cells from TC-1 tumors were stained
with the following fluorophore-conjugated antibodies: PeCy7-con-
jugated anti-CD11b, FITC-conjugated anti-Gr1 and APC-conju-
gated anti-CD3 (eBioscience, catalog nr. 25-0112-82, 11-5931-
82, 17-0031-82). Cells were washed and sorted on a FACS
MoFloAstrios (Beckman Coulter) based on forward and sideward
scatter. Cells were positively sorted into CD11bCGr1C MDSCs
and negatively sorted into CD3C T cells. As determined by flow
cytometric re-analysis, the purity of the sortedMDSCs was>92%.
Spleens cells isolated from donor mice immunized twice with
5 £ 106 SFVeE6,7 particles were cultured in 96-well round bot-
tom plates for 7 d. On day 0 of culture, flow-sorted MDSCs, iso-
lated from TC-1 tumors, were added at different ratios to these
cultures. On day 4 of culture, cells were labeled with carboxy-
fluorescein succinimidyl ester (CFSE; Invitrogen, catalog nr.
C34554) for 10 min at 37oC. On day 5 of co-culture, recombi-
nant IL-2 was added to the co-culture at a concentration of 5U/
mL. As negative controls, splenocytes were cultured without
stimulant. As positive controls, splenocytes were stimulated and
cultured in the absence of MDSCs. At the end of the co-culture
period, cells were collected and used for analysis.
MDSCs, MHC Class I tetramer staining and
cytofluorimetric analysis
To determine the numbers of MDSCs, cells were stained with
PE-Cy7-conjugated anti-CD11b, and FITC-conjugated anti-
Gr1, (clone RB6-8C5; eBioscience, catalog nr. 25-0112-82, 11-
5931-82) that binds with high affinity to the Ly-6G epitope and
a lower affinity to the Ly-6C epitope.53 For Treg analysis, cells
were stained with PE-conjugated anti-CD4 and intracellular
with Alexa700-conjugated anti-FoxP3 (eBioscience, catalog nr.
12-0043-82, 56-5773-82). To characterize CD8C T cells specific
for the antigenic epitope HPV16 E749-57 peptide RAHYNIVTF,
1£106 splenocytes or 1–2 £ 106 cells isolated from tumors were
washed with FACS buffer (PBS containing 0.5% bovine serum
albumin [BSA]) and stained with PE-conjugated H2-Db RAHY-
NIVTF tetramers. Subsequently, cells were stained with anti-
CD8 conjugated to PE-Cy7 (eBioscience) and FITC or
Alexa700-conjugated anti-CD69 (eBioscience, catalog nr. 25-
0081-82, 17-0691-82) antibodies. Next, cells were washed twice
and analyzed by cytofluorimetry using a LSR-II (BD Biosciences)
flow cytometer. Dead cells were excluded either by LIVE/
DEAD Fixable Dead Cell Stain Kit (Invitrogen, catalog nr.
L34955) or by 4, 6-diamino-2-phenylindole (DAPI, Invitrogen,
catalog nr. D3571). Pe-Cy7-conjugated anti-CD11b and PE-
conjugated anti-CD11c (eBioscience, catalog nr. 25-0112-82,
12-0114-82) were used to determine neutrophil and dendritic
cell levels, respectively.
Immunohistochemistry
Immunohistochemistry was performed as described before.2
Briefly, 4-micrometer thick frozen tumor sections were fixed in
cold acetone for 10 min. To identify MDSCs, the primary anti-
body used was a rat anti-mouse Ly6G-Ly6C (lymphocyte antigen
6 complex, locus C/G) monoclonal antibody (BD Biosciences,
catalog nr. 562737). To identify CD8C T cells, the primary anti-
body used was a rat anti-mouse CD8 antibody (Abcam, catalog
nr. ab3081). Sections were incubated with the primary antibody
for 60 min. The secondary antibody used was a goat anti-rat,
HRP labeled antibody (AbD Serotec, catalog nr. STAR112P)
diluted to a ratio of 1:100 in PBS with 1% BSA. Sections were
incubated with the secondary antibody for 30 min. Development
of the color reaction was performed with the commercially
available AEC kit and background was stained with Mayers
Hematoxylin (Sigma Aldrich, catalog nr. MHS1-100ML).
ImmunoHistoMount (Sigma Aldrich, catalog nr. I1161-30ML)
mounting medium was applied. Slides were covered with cover
slips and scanned using a Hamamatsu NanoZoomer 2.0HT.
Real-time polymerase chain reaction
RNA from MDSCs previously isolated from TC-1 tumors
and sorted using a MoFloAstrios cell sorter (Beckman Coulter)
was extracted with an RNeasy Mini kit (Qiagen, catalog nr.
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74104), following manufacturers’ protocol. The amount of RNA
per sample was equalized to 0.05 mg/mL in RNase-free water.
The Verso Reverse Transcriptase kit (Thermo Scientific, catalog
nr. # AB-1453/A) was used to synthesize cDNA, according to
the manufacturer’s protocol. Real-time PCR was performed using
a StepOne real-time PCR system from Applied Biosystems. The
reaction was conducted with 1 mL cDNA, 12.5 mL Absolute
QPCR SYBR Green ROX Mix (Thermo Scientific, catalog nr. #
AB-4105/A) and targeted gene-specific primers (for primer sequen-
ces [Eurogentec] see Table S1). Quantification of b-actin was used
for sample normalization. As negative controls, RNase-free water
was used instead of sample cDNA. The 2(¡ddCt) method was
used to calculate the relative induction of chemokines.54
Statistical analysis
Data presented as mean § standard deviation (SD) are repre-
sentative of at least two independent experiments. Statistical dif-
ferences between two groups were determined by a 2-tailed
Mann-Whitney U test or unpaired t test. Statistical differences
between several groups were determined by a non-parametric
rank sum test for one-way ANOVA, followed by the multiple
comparison procedure Kruskal-Wallis. All p-values of 0.05 or
lower were considered significant. All statistical analyses were per-
formed using GraphPad Prism software, version 5.0.0.288
(GraphPad software, San Diego).
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